These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 25904513)
21. [Treatment with the first glycylcycline--tigecycline]. Musch A Med Monatsschr Pharm; 2006 May; 29(5):191-2. PubMed ID: 16719269 [No Abstract] [Full Text] [Related]
22. Tigecycline: benefits and risks. Cai Y; Wang R Lancet Infect Dis; 2011 Nov; 11(11):804-5. PubMed ID: 21784707 [No Abstract] [Full Text] [Related]
23. [Bacterial resistance and a new antibiotic: tigecycline]. Gobernado M Rev Esp Quimioter; 2006 Sep; 19(3):209-19. PubMed ID: 17099789 [No Abstract] [Full Text] [Related]
24. Francis Tally and the discovery and development of tigecycline: a personal reminiscence. Projan SJ Clin Infect Dis; 2010 Jan; 50 Suppl 1():S24-5. PubMed ID: 20067389 [TBL] [Abstract][Full Text] [Related]
28. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. Nix DE; Matthias KR J Antimicrob Chemother; 2010 Jun; 65(6):1311-2. PubMed ID: 20378673 [No Abstract] [Full Text] [Related]
29. What role for tigecycline in infections? BMJ Group Drug Ther Bull; 2008 Aug; 46(8):62-4. PubMed ID: 18687585 [TBL] [Abstract][Full Text] [Related]
30. Effectiveness and safety of tigecycline: focus on use for approved indications. Vardakas KZ; Rafailidis PI; Falagas ME Clin Infect Dis; 2012 Jun; 54(11):1672-4. PubMed ID: 22431809 [No Abstract] [Full Text] [Related]
31. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Burkhardt O; Rauch K; Kaever V; Hadem J; Kielstein JT; Welte T Int J Antimicrob Agents; 2009 Jul; 34(1):101-2. PubMed ID: 19278835 [No Abstract] [Full Text] [Related]
32. Antimicrobial activity of tigecycline against bacterial isolates from intensive care units in a teaching hospital in Central Saudi Arabia. Somily AM; Al-Khattaf AS; Kambal AM Saudi Med J; 2010 Jan; 31(1):18-24. PubMed ID: 20062893 [TBL] [Abstract][Full Text] [Related]
33. Microbial isolation and emergence of antimicrobial resistance associated with tigecycline usage. Chen LY; Chen TC; Chen YH; Lin CY; Lin WR; Lu PL J Microbiol Immunol Infect; 2011 Oct; 44(5):352-7. PubMed ID: 21524975 [TBL] [Abstract][Full Text] [Related]
34. Tigecycline: an antibiotic for the twenty-first century. Dryden M J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii3-4. PubMed ID: 23772044 [TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid penetration of tigecycline. Pallotto C; Fiorio M; D'Avolio A; Sgrelli A; Baldelli F; Di Perri G; De Socio GV Scand J Infect Dis; 2014 Jan; 46(1):69-72. PubMed ID: 24131423 [TBL] [Abstract][Full Text] [Related]
36. Off-label use of antibiotics in hospitalized patients: focus on tigecycline. Curcio D J Antimicrob Chemother; 2009 Dec; 64(6):1344-6. PubMed ID: 19759045 [No Abstract] [Full Text] [Related]
37. [Experience with tigecycline in the treatment of multiresistant germs in the ICU]. Curiel Balsera E; Poullet Brea AM; Prieto Palomino MÁ Med Intensiva; 2011; 35(5):319-20. PubMed ID: 21130538 [No Abstract] [Full Text] [Related]
38. Tigecycline: an expanded broad-spectrum intravenous antibiotic. Preface and summary. Felmingham D J Chemother; 2005 Aug; 17 Suppl 1():3-4. PubMed ID: 16429623 [No Abstract] [Full Text] [Related]
39. A review of tigecycline--the first glycylcycline. Peterson LR Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S215-22. PubMed ID: 19134522 [TBL] [Abstract][Full Text] [Related]
40. Off-label prescription of tigecycline: clinical and microbiological characteristics and outcomes. Conde-Estévez D; Grau S; Horcajada JP; Luque S Int J Antimicrob Agents; 2010 Nov; 36(5):471-2. PubMed ID: 20828992 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]